Transcriptome profiling analysis reveals that CXCL2 is involved in anlotinib resistance in human lung cancer cells

BACKGROUND: Anlotinib has been demonstrated its anti-tumor efficacy on non-small cell lung cancer (NSCLC) in clinical trials at 3rd line. However, anlotinib resistance occurs during its administration, and the underlying mechanism is still unclear. METHODS: Anlotinib resistant lung cancer cell line...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Med Genomics
Main Authors: Lu, Jun, Xu, Wei, Qian, Jie, Wang, Shuyuan, Zhang, Bo, Zhang, Lele, Qiao, Rong, Hu, Minjuan, Zhao, Yiming, Zhao, Xiaodong, Han, Baohui
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2019
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6416828/
https://ncbi.nlm.nih.gov/pubmed/30871526
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12920-019-0482-y
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados